Form 4: Ionis Director Sells Shares Under 10b5-1 Plan

Ionis Pharmaceuticals Director B. Lynne Parshall sold 5,000 shares of common stock for approximately $82.72 per share under a pre-arranged trading plan.

Summary

• B. Lynne Parshall, a Director of Ionis Pharmaceuticals Inc. (IONS), sold 5,000 shares of common stock.
• The transaction occurred on February 11, 2026.
• The shares were sold at a weighted average price of $82.7177 per share, with individual sales ranging from $82.585 to $82.97.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on May 6, 2025.
• Following the transaction, B. Lynne Parshall beneficially owns 56,344 shares of Ionis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-arranged 10b5-1 trading plan, which typically indicates personal financial planning rather than a change in company outlook.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and typically pre-scheduled, often for personal financial planning, rather than indicating a change in the insider's view of the company's prospects. This is a standard practice in the biotechnology and pharmaceutical sectors for executives and directors to manage their equity holdings.

Key Dates

Recommendation

The sale of shares by a director under a pre-arranged Rule 10b5-1 trading plan is a routine event for personal financial management and does not typically signal a change in the company's fundamental prospects. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company performance and market conditions.

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Sale, B. Lynne Parshall, Director, 10b5-1 Plan, Biotechnology, Pharmaceuticals